Recombinant Vector Vaccine Market - Industry Forecast 2030

Recombinant Vector Vaccine Market Size – Industry Structure Evaluation, Demand Drivers Analysis, Regional Growth Analysis and Identification, Competitive Positioning Review & Global Market Size Forecast to 2030

7.2%

CAGR (2024-2030)

19.14 USD Bn.

Market Size

318

Report Pages

139

Market Tables

Overview

Recombinant Vector Vaccine Market is expected to grow at a CAGR of 7.2% during the forecast period. Global Recombinant Vector Vaccine Market is expected to reach US$ 31.14 Bn. by 2030.

Recombinant vector vaccines are live replicating viruses that are engineered to carry extra genes derived from a pathogen and these extra genes produce proteins against which we want to generate immunity.

The report on the Global market gives an estimation of the development of the market based on historical studies and also provides forecasts on the basis of comprehensive research. The report gives a complete market analysis for the forecast period from 2024 to 2030. The market is divided into various segments with an in-depth outlook of the competitors and a listing of the profiled key players. Leading players in the global market include Sanai, Pfizer Inc., Novartis AG, Neuron Biotech, and Merck and Company. The market size in terms of revenue and volume is calculated and provided for the study period along with the dynamics of the market such as the drivers and the restraints.To know about the Research Methodology :- Request Free Sample Report

Dynamics

The need for reducing the high prevalence of viral infections such as human papillomavirus infection, hepatitis B, COVID-19, and others are imposing higher demand for recombinant vector vaccines worldwide. Governments from all countries are focusing on implementing vaccination programs and policies that are helping professionals tackle the increasing burden of infectious diseases. This is expected to drive the global market during the forecast period.

The most significant driver for the growth of the global market is the full-fledged advantage of recombinant properties in providing effectiveness and safety to the patient get immunized. The vaccines can be produced quickly and in larger quantities, which eliminates the risk of a vaccine shortage. The above-mentioned factors, coupled with the growing population, are expected to drive the global market during the forecast period.

Market is segmented by vector, disease type, and region.

The recombinant viral vector vaccines segment holds the maximum share of the global market.

Recombinant viral vector vaccines produce proteins against, which we want to generate immunity. The advances in immunology, molecular biology, biochemistry, genomics, and proteomics have added new perspectives to the recombinant viral vector vaccinology field. Live recombinant viral vector vaccines effectively stimulate the immune system as in natural infections and have intrinsic adjuvant properties. The recombinant viral vector vaccines can induce strong long-term cellular immune responses and combine different antigen delivery systems to broaden the immune response. As a result recombinant viral vector vaccines are expected to command the largest market share of xx% by 2030.

Most current recombinant viral vector vaccines owe their success on their ability to target pathogens that have low antigenic variability and for which protection depends on antibody-mediated immunity. Hence this kind of vaccine is mostly preferred for children suffering from polio, tetanus, diphtheria, measles, and hepatitis B, among others. Hence the recombinant viral vector vaccines segment dominates the global market in the forecast period.

Viral segment commanded largest market share of xx% by 2030.

Emerging and re-emerging infectious diseases and the recent increase in prevalence of immunodeficiency virus (HIV) and severe acute respiratory syndrome (SARS) - associated coronavirus (SARS-Cove) is driving the global market during the forecast period.

The large size of the genome, discontinuous transcription, the presence of transcriptionally active full and sub-genomic length RNAs in viruses are the characteristics, which support high recombination rates in viruses, and hence global recombinant the vector vaccine market is driving in the forecast period.

North America is expected to command largest market share of xx% by 2030.

The developed scientific infrastructure along with the high awareness levels among people fosters the growth of the global market in this region. A large number of pharmaceutical companies present in this region and the use of vector vaccines to treat infectious diseases are driving the global recombinant vaccines market. Continuous R & D investments by key players and rapid adoption of efficient vaccines across the region are expected to drive the market growth from North America.

Availability of advances molecular and genetic engineering instruments in the region is the major factor responsible to boost the R & D leading to the introduction of novel vaccines. As a result, North America is expected to drive the global market in the forecast period.

Recombinant Vector Vaccine Market Scope: Inquire before buying

Global Recombinant Vector Vaccine Market
Report Coverage	Details
Base Year:	2023	Forecast Period:	2024-2030
Historical Data:	2018 to 2023	Market Size in 2023:	US $ 19.14 Bn.
Forecast Period 2024 to 2030 CAGR:	7.2%	Market Size in 2030:	US $ 31.14 Bn.
Segments Covered:	by Vector	Recombinant viral vector vaccines Recombinant bacterial vector vaccines
Segments Covered:	by Disease Type	Viral Bacterial infections

Recombinant Vector Vaccine Market, by Region

Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
North America (United States, Canada and Mexico)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)

Recombinant Vector Vaccine Market, Key Players are:

1. Sanai
2. Pfizer Inc.
3. Novartis AG
4. Neuron Biotech
5. Merck and Company
6. GlaxoSmithKline plc.
7. CSL Limited
8. Biological E
9. Bharat Biotech
10. Serum Institute of India Private Limited
11. CNBG
12. Protein Science Corporation
13. Green Cross Corporation
14. Bayer AG

Frequently Asked Questions:

1. Which region has the largest share in Global Recombinant Vector Vaccine Market?
Ans: North America region held the highest share in 2023.

2. What is the growth rate of Global Recombinant Vector Vaccine Market?
Ans: The Global Recombinant Vector Vaccine Market is growing at a CAGR of 7.2% during forecasting period 2024-2030.

3. What is scope of the Global Recombinant Vector Vaccine market report?
Ans: Global Recombinant Vector Vaccine Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global Recombinant Vector Vaccine market?
Ans: The important key players in the Global Recombinant Vector Vaccine Market are – Sanai, Pfizer Inc., Novartis AG, Neuron Biotech, Merck and Company, GlaxoSmithKline plc., CSL Limited, Biological E, Bharat Biotech, Serum Institute of India Private Limited, CNBG, Protein Science Corporation, Green Cross Corporation, and Bayer AG

5. What is the study period of this market?
Ans: The Global Recombinant Vector Vaccine Market is studied from 2023 to 2030.

Global Recombinant Vector Vaccine Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Recombinant Vector Vaccine Market Size, By Market Value (US$ Mn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Recombinant Vector Vaccine Market Analysis and Forecast 6.1. Recombinant Vector Vaccine Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Recombinant Vector Vaccine Market Analysis and Forecast, By Vector 7.1. Introduction and Definition 7.2. Key Findings 7.3. Recombinant Vector Vaccine Market Value Share Analysis, By Vector 7.4. Recombinant Vector Vaccine Market Size (US$ Mn) Forecast, By Vector 7.5. Recombinant Vector Vaccine Market Analysis, By Vector 7.6. Recombinant Vector Vaccine Market Attractiveness Analysis, By Vector 8. Global Recombinant Vector Vaccine Market Analysis and Forecast, By Disease Type 8.1. Introduction and Definition 8.2. Key Findings 8.3. Recombinant Vector Vaccine Market Value Share Analysis, By Disease Type 8.4. Recombinant Vector Vaccine Market Size (US$ Mn) Forecast, By Disease Type 8.5. Recombinant Vector Vaccine Market Analysis, By Disease Type 8.6. Recombinant Vector Vaccine Market Attractiveness Analysis, By Disease Type 9. Global Recombinant Vector Vaccine Market Analysis, By Region 9.1. Recombinant Vector Vaccine Market Value Share Analysis, By Region 9.2. Recombinant Vector Vaccine Market Size (US$ Mn) Forecast, By Region 9.3. Recombinant Vector Vaccine Market Attractiveness Analysis, By Region 10. North America Recombinant Vector Vaccine Market Analysis 10.1. Key Findings 10.2. North America Recombinant Vector Vaccine Market Overview 10.3. North America Recombinant Vector Vaccine Market Value Share Analysis, By Vector 10.4. North America Recombinant Vector Vaccine Market Forecast, By Vector 10.4.1. Recombinant viral vector vaccines 10.4.2. Recombinant bacterial vector vaccines 10.5. North America Recombinant Vector Vaccine Market Value Share Analysis, By Disease Type 10.6. North America Recombinant Vector Vaccine Market Forecast, By Disease Type 10.6.1. Viral 10.6.2. Bacterial infections 10.7. North America Recombinant Vector Vaccine Market Value Share Analysis, By Country 10.8. North America Recombinant Vector Vaccine Market Forecast, By Country 10.8.1. U.S. 10.8.2. Canada 10.8.3. Mexico 10.9. North America Recombinant Vector Vaccine Market Analysis, By Country 10.10. U.S. Recombinant Vector Vaccine Market Forecast, By Vector 10.10.1. Recombinant viral vector vaccines 10.10.2. Recombinant bacterial vector vaccines 10.11. U.S. Recombinant Vector Vaccine Market Forecast, By Disease Type 10.11.1. Viral 10.11.2. Bacterial infections 10.12. Canada Recombinant Vector Vaccine Market Forecast, By Vector 10.12.1. Recombinant viral vector vaccines 10.12.2. Recombinant bacterial vector vaccines 10.13. Canada Recombinant Vector Vaccine Market Forecast, By Disease Type 10.13.1. Viral 10.13.2. Bacterial infections 10.14. Mexico Recombinant Vector Vaccine Market Forecast, By Vector 10.14.1. Recombinant viral vector vaccines 10.14.2. Recombinant bacterial vector vaccines 10.15. Mexico Recombinant Vector Vaccine Market Forecast, By Disease Type 10.15.1. Viral 10.15.2. Bacterial infections 10.16. North America Recombinant Vector Vaccine Market Attractiveness Analysis 10.16.1. By Vector 10.16.2. By Disease Type 10.17. PEST Analysis 10.18. Key Trends 10.19. Key Developments 11. Europe Recombinant Vector Vaccine Market Analysis 11.1. Key Findings 11.2. Europe Recombinant Vector Vaccine Market Overview 11.3. Europe Recombinant Vector Vaccine Market Value Share Analysis, By Vector 11.4. Europe Recombinant Vector Vaccine Market Forecast, By Vector 11.4.1. Recombinant viral vector vaccines 11.4.2. Recombinant bacterial vector vaccines 11.5. Europe Recombinant Vector Vaccine Market Value Share Analysis, By Disease Type 11.6. Europe Recombinant Vector Vaccine Market Forecast, By Disease Type 11.6.1. Viral 11.6.2. Bacterial infections 11.7. Europe Recombinant Vector Vaccine Market Value Share Analysis, By Country 11.8. Europe Recombinant Vector Vaccine Market Forecast, By Country 11.8.1. Germany 11.8.2. U.K. 11.8.3. France 11.8.4. Italy 11.8.5. Spain 11.8.6. Sweden 11.8.7. CIS countries 11.8.8. Rest of Europe 11.9. Germany Recombinant Vector Vaccine Market Forecast, By Vector 11.9.1. Recombinant viral vector vaccines 11.9.2. Recombinant bacterial vector vaccines 11.10. Germany Recombinant Vector Vaccine Market Forecast, By Disease Type 11.10.1. Viral 11.10.2. Bacterial infections 11.11. U.K. Recombinant Vector Vaccine Market Forecast, By Vector 11.11.1. Recombinant viral vector vaccines 11.11.2. Recombinant bacterial vector vaccines 11.12. U.K. Recombinant Vector Vaccine Market Forecast, By Disease Type 11.12.1. Viral 11.12.2. Bacterial infections 11.13. France Recombinant Vector Vaccine Market Forecast, By Vector 11.13.1. Recombinant viral vector vaccines 11.13.2. Recombinant bacterial vector vaccines 11.14. France Recombinant Vector Vaccine Market Forecast, By Disease Type 11.14.1. Viral 11.14.2. Bacterial infections 11.15. Italy Recombinant Vector Vaccine Market Forecast, By Vector 11.15.1. Recombinant viral vector vaccines 11.15.2. Recombinant bacterial vector vaccines 11.16. Italy Recombinant Vector Vaccine Market Forecast, By Disease Type 11.16.1. Viral 11.16.2. Bacterial infections 11.17. Spain Recombinant Vector Vaccine Market Forecast, By Vector 11.17.1. Recombinant viral vector vaccines 11.17.2. Recombinant bacterial vector vaccines 11.18. Spain Recombinant Vector Vaccine Market Forecast, By Disease Type 11.18.1. Viral 11.18.2. Bacterial infections 11.19. Sweden Recombinant Vector Vaccine Market Forecast, By Vector 11.19.1. Recombinant viral vector vaccines 11.19.2. Recombinant bacterial vector vaccines 11.20. Sweden Recombinant Vector Vaccine Market Forecast, By Disease Type 11.20.1. Viral 11.20.2. Bacterial infections 11.21. CIS countries Recombinant Vector Vaccine Market Forecast, By Vector 11.21.1. Recombinant viral vector vaccines 11.21.2. Recombinant bacterial vector vaccines 11.22. CIS countries Recombinant Vector Vaccine Market Forecast, By Disease Type 11.22.1. Viral 11.22.2. Bacterial infections 11.23. Rest of Europe Recombinant Vector Vaccine Market Forecast, By Vector 11.23.1. Recombinant viral vector vaccines 11.23.2. Recombinant bacterial vector vaccines 11.24. Rest of Europe Recombinant Vector Vaccine Market Forecast, By Disease Type 11.24.1. Viral 11.24.2. Bacterial infections 11.25. Europe Recombinant Vector Vaccine Market Attractiveness Analysis 11.25.1. By Disease Type 11.25.2. By Vector 11.26. PEST Analysis 11.27. Key Trends 11.28. Key Developments 12. Asia Pacific Recombinant Vector Vaccine Market Analysis 12.1. Key Findings 12.2. Asia Pacific Recombinant Vector Vaccine Market Overview 12.3. Asia Pacific Recombinant Vector Vaccine Market Value Share Analysis, By Vector 12.4. Asia Pacific Recombinant Vector Vaccine Market Forecast, By Vector 12.4.1. Recombinant viral vector vaccines 12.4.2. Recombinant bacterial vector vaccines 12.5. Asia Pacific Recombinant Vector Vaccine Market Value Share Analysis, By Disease Type 12.6. Asia Pacific Recombinant Vector Vaccine Market Forecast, By Disease Type 12.6.1. Viral 12.6.2. Bacterial infections 12.7. Asia Pacific Recombinant Vector Vaccine Market Value Share Analysis, By Country 12.8. Asia Pacific Recombinant Vector Vaccine Market Forecast, By Country 12.8.1. China 12.8.2. India 12.8.3. Japan 12.8.4. South Korea 12.8.5. Australia 12.8.6. ASEAN 12.8.7. Rest of Asia Pacific 12.9. Asia Pacific Recombinant Vector Vaccine Market Analysis, By Country 12.10. China Recombinant Vector Vaccine Market Forecast, By Vector 12.10.1. Recombinant viral vector vaccines 12.10.2. Recombinant bacterial vector vaccines 12.11. China Recombinant Vector Vaccine Market Forecast, By Disease Type 12.11.1. Viral 12.11.2. Bacterial infections 12.12. India Recombinant Vector Vaccine Market Forecast, By Vector 12.12.1. Recombinant viral vector vaccines 12.12.2. Recombinant bacterial vector vaccines 12.13. India Recombinant Vector Vaccine Market Forecast, By Disease Type 12.13.1. Viral 12.13.2. Bacterial infections 12.14. Japan Recombinant Vector Vaccine Market Forecast, By Vector 12.14.1. Recombinant viral vector vaccines 12.14.2. Recombinant bacterial vector vaccines 12.15. Japan Recombinant Vector Vaccine Market Forecast, By Disease Type 12.15.1. Viral 12.15.2. Bacterial infections 12.16. South Korea Recombinant Vector Vaccine Market Forecast, By Vector 12.16.1. Recombinant viral vector vaccines 12.16.2. Recombinant bacterial vector vaccines 12.17. South Korea Recombinant Vector Vaccine Market Forecast, By Disease Type 12.17.1. Viral 12.17.2. Bacterial infections 12.18. Australia Recombinant Vector Vaccine Market Forecast, By Vector 12.18.1. Recombinant viral vector vaccines 12.18.2. Recombinant bacterial vector vaccines 12.19. Australia Recombinant Vector Vaccine Market Forecast, By Disease Type 12.19.1. Viral 12.19.2. Bacterial infections 12.20. ASEAN Recombinant Vector Vaccine Market Forecast, By Vector 12.20.1. Recombinant viral vector vaccines 12.20.2. Recombinant bacterial vector vaccines 12.21. ASEAN Recombinant Vector Vaccine Market Forecast, By Disease Type 12.21.1. Viral 12.21.2. Bacterial infections 12.22. Rest of Asia Pacific Recombinant Vector Vaccine Market Forecast, By Vector 12.22.1. Recombinant viral vector vaccines 12.22.2. Recombinant bacterial vector vaccines 12.23. Rest of Asia Pacific Recombinant Vector Vaccine Market Forecast, By Disease Type 12.23.1. Viral 12.23.2. Bacterial infections 12.24. Asia Pacific Recombinant Vector Vaccine Market Attractiveness Analysis 12.24.1. By Vector 12.24.2. By Disease Type 12.25. PEST Analysis 12.26. Key Trends 12.27. Key Developments 13. Middle East & Africa Recombinant Vector Vaccine Market Analysis 13.1. Key Findings 13.2. Middle East & Africa Recombinant Vector Vaccine Market Overview 13.3. Middle East & Africa Recombinant Vector Vaccine Market Value Share Analysis, By Vector 13.4. Middle East & Africa Recombinant Vector Vaccine Market Forecast, By Vector 13.4.1. Recombinant viral vector vaccines 13.4.2. Recombinant bacterial vector vaccines 13.5. Middle East & Africa Recombinant Vector Vaccine Market Value Share Analysis, By Disease Type 13.6. Middle East & Africa Recombinant Vector Vaccine Market Forecast, By Disease Type 13.6.1. Viral 13.6.2. Bacterial infections 13.7. Middle East & Africa Recombinant Vector Vaccine Market Value Share Analysis, By Country 13.8. Middle East & Africa Recombinant Vector Vaccine Market Forecast, By Country 13.8.1. GCC Countries 13.8.2. South Africa 13.8.3. Nigeria 13.8.4. Egypt 13.8.5. Rest of Middle East & Africa 13.9. Middle East & Africa Recombinant Vector Vaccine Market Analysis, By Country 13.10. GCC Countries Recombinant Vector Vaccine Market Forecast, By Vector 13.10.1. Recombinant viral vector vaccines 13.10.2. Recombinant bacterial vector vaccines 13.11. GCC Countries Recombinant Vector Vaccine Market Forecast, By Disease Type 13.11.1. Viral 13.11.2. Bacterial infections 13.12. South Africa Recombinant Vector Vaccine Market Forecast, By Vector 13.12.1. Recombinant viral vector vaccines 13.12.2. Recombinant bacterial vector vaccines 13.13. South Africa Recombinant Vector Vaccine Market Forecast, By Disease Type 13.13.1. Viral 13.13.2. Bacterial infections 13.14. Nigeria Recombinant Vector Vaccine Market Forecast, By Vector 13.14.1. Recombinant viral vector vaccines 13.14.2. Recombinant bacterial vector vaccines 13.15. Nigeria Recombinant Vector Vaccine Market Forecast, By Disease Type 13.15.1. Viral 13.15.2. Bacterial infections 13.16. Egypt Recombinant Vector Vaccine Market Forecast, By Vector 13.16.1. Recombinant viral vector vaccines 13.16.2. Recombinant bacterial vector vaccines 13.17. Egypt Recombinant Vector Vaccine Market Forecast, By Disease Type 13.17.1. Viral 13.17.2. Bacterial infections 13.18. Rest of Middle East & Africa Recombinant Vector Vaccine Market Forecast, By Vector 13.18.1. Recombinant viral vector vaccines 13.18.2. Recombinant bacterial vector vaccines 13.19. Rest of Middle East & Africa Recombinant Vector Vaccine Market Forecast, By Disease Type 13.19.1. Viral 13.19.2. Bacterial infections 13.20. Middle East & Africa Recombinant Vector Vaccine Market Attractiveness Analysis 13.20.1. By Vector 13.20.2. By Disease Type 13.21. PEST Analysis 13.22. Key Trends 13.23. Key Developments 14. South America Recombinant Vector Vaccine Market Analysis 14.1. Key Findings 14.2. South America Recombinant Vector Vaccine Market Overview 14.3. South America Recombinant Vector Vaccine Market Value Share Analysis, By Vector 14.4. South America Recombinant Vector Vaccine Market Forecast, By Vector 14.4.1. Recombinant viral vector vaccines 14.4.2. Recombinant bacterial vector vaccines 14.5. South America Recombinant Vector Vaccine Market Value Share Analysis, By Disease Type 14.6. South America Recombinant Vector Vaccine Market Forecast, By Disease Type 14.6.1. Viral 14.6.2. Bacterial infections 14.7. South America Recombinant Vector Vaccine Market Value Share Analysis, By Country 14.8. South America Recombinant Vector Vaccine Market Forecast, By Country 14.8.1. Brazil 14.8.2. Colombia 14.8.3. Argentina 14.8.4. Rest of South America 14.9. South America Recombinant Vector Vaccine Market Analysis, By Country 14.10. Brazil Recombinant Vector Vaccine Market Forecast, By Vector 14.10.1. Recombinant viral vector vaccines 14.10.2. Recombinant bacterial vector vaccines 14.11. Brazil Recombinant Vector Vaccine Market Forecast, By Disease Type 14.11.1. Viral 14.11.2. Bacterial infections 14.12. Colombia Recombinant Vector Vaccine Market Forecast, By Vector 14.12.1. Recombinant viral vector vaccines 14.12.2. Recombinant bacterial vector vaccines 14.13. Colombia Recombinant Vector Vaccine Market Forecast, By Disease Type 14.13.1. Viral 14.13.2. Bacterial infections 14.14. Argentina Recombinant Vector Vaccine Market Forecast, By Vector 14.14.1. Recombinant viral vector vaccines 14.14.2. Recombinant bacterial vector vaccines 14.15. Argentina Recombinant Vector Vaccine Market Forecast, By Disease Type 14.15.1. Viral 14.15.2. Bacterial infections 14.16. Rest of South America Recombinant Vector Vaccine Market Forecast, By Vector 14.16.1. Recombinant viral vector vaccines 14.16.2. Recombinant bacterial vector vaccines 14.17. Rest of South America Recombinant Vector Vaccine Market Forecast, By Disease Type 14.17.1. Viral 14.17.2. Bacterial infections 14.18. South America Recombinant Vector Vaccine Market Attractiveness Analysis 14.18.1. By Vector 14.18.2. By Disease Type 14.19. PEST Analysis 14.20. Key Trends 14.21. Key Developments 15. Company Profiles 15.1. Market Share Analysis, By Company 15.2. Competition Matrix 15.2.1. Competitive Benchmarking of key players By price, presence, market share, Component, and R&D investment 15.2.2. New Product Launches and Product Enhancements 15.2.3. Market Consolidation 15.2.3.1. M&A By Regions, Investment and Component 15.2.3.2. M&A Key Players, Forward Integration and Backward Integration 15.3. Company Profiles: Key Players 15.3.1. Sanai 15.3.1.1. Company Overview 15.3.1.2. Financial Overview 15.3.1.3. Product Portfolio 15.3.1.4. Business Strategy 15.3.1.5. Recent Developments 15.3.1.6. Development Footprint 15.3.2. Pfizer Inc. 15.3.3. Novartis AG 15.3.4. Neuron Biotech 15.3.5. Merck and Company 15.3.6. GlaxoSmithKline plc. 15.3.7. CSL Limited 15.3.8. Biological E 15.3.9. Bharat Biotech 15.3.10. Serum Institute of India Private Limited 15.3.11. CNBG 15.3.12. Protein Science Corporation 15.3.13. Green Cross Corporation 15.3.14. Bayer AG 16. Primary key Insights

Global Recombinant Vector Vaccine Market

Choose License Type